676134-50-2Relevant academic research and scientific papers
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors
Ng, Raymond A.,Sun, Minghua,Bowers, Simeon,Hom, Roy K.,Probst, Gary D.,John, Varghese,Fang, Lawrence Y.,Maillard, Michel,Gailunas, Andrea,Brogley, Louis,Neitz, R. Jeffrey,Tung, Jay S.,Pleiss, Michael A.,Konradi, Andrei W.,Sham, Hing L.,Dappen, Michael S.,Adler, Marc,Yao, Nanhua,Zmolek, Wes,Nakamura, David,Quinn, Kevin P.,Sauer, John-Michael,Bova, Michael P.,Ruslim, Lany,Artis, Dean R.,Yednock, Ted A.
, p. 4674 - 4679 (2013/08/23)
The structure activity relationship of the prime region of conformationally restricted hydroxyethylamine (HEA) BACE inhibitors is described. Variation of the P1′ region provided selectivity over Cat-D with a series of 2,2-dioxo-isothiochromanes and optimi
2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES
-
Page/Page column 151-152, (2008/06/13)
Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer’s disease and other diseases characterized by deposition of A beta peptide in a mammal.
METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS
-
Page/Page column 252-253, (2010/02/14)
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
